Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.
According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.
Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.
Related Articles
WUHAN YOUJI (02881) established a new non-wholly owned subsidiary and entered into multiple transactions.
GigaDevice Semiconductor Inc. (603986.SH): The preliminary price range for the H shares issuance is determined to be between 132 Hong Kong dollars and 162 Hong Kong dollars.
OmniVision Integrated Circuits Group, Inc. (603501.SH): The H-share issuance price shall not exceed HK$104.80 per share.
WUHAN YOUJI (02881) established a new non-wholly owned subsidiary and entered into multiple transactions.
GigaDevice Semiconductor Inc. (603986.SH): The preliminary price range for the H shares issuance is determined to be between 132 Hong Kong dollars and 162 Hong Kong dollars.
OmniVision Integrated Circuits Group, Inc. (603501.SH): The H-share issuance price shall not exceed HK$104.80 per share.
